Skip to content
Quant500 - Quantitative Analysis
Search ticker or company...
ES | EN

Company Profile: Baxter International Inc. (BAX)

BAX insider trades (13 months) →

$25.49 +5.24% vs. previous close · Market cap $13.19B

Today's multi-factor rank: 236 of 461 · see the ranking

Quant500 Scores
Momentum
5.7/10
Value
4.4/10
Growth
6.3/10
Quality
3.1/10
Multifactor
4.9/10

Market and Valuation

Price & Market

Prev Close Price:$24.22
Open:$24.04
Day's Low:$23.92
Day's High:$25.57
Bid / Ask:-
Market Cap:13.19B
Enterprise Value:19.34B

52-Week Range

52-Week Low:$15.73
52-Week High:$30.00
Current position in 52-week range
52w Low-52w High
50-Day Avg:$24.54
200-Day Avg:$21.36

Volume

Volume Today:9,397,283
Avg Volume (3m):6,590,842
Avg Volume (10d):8,730,750
52-Week Change:+35.01%
vs S&P 500, 52 weeks:-
Beta:0.67

Valuation Multiples

P/E (trailing):n/a (loss)

Diluted EPS for the last 12 months: the four quarters ended Sep 30, 2026, from the accounts filed with the SEC on Oct 29, 2026. With negative EPS a P/E means nothing, so it is not shown.

P/E (forward):12.48
PEG Ratio:36.68
Price / Book:2.03
Price / Sales (TTM):1.14
EV / Revenue:1.67
EV / EBITDA:10.55

Dividends

Current yield:0.17%
Annual Dividend Rate:$0.04
Dividend Trailing:$0.04
Yield Trailing:0.17%
5-Year Avg Yield:1.50%
Payout Ratio:154.67%
Last Ex-Dividend Date:-

Valuation Context

P/E vs sector (indicative)

Most Recent Quarter:-
Fiscal Year (Next):-

Loading historical OHLCV database...

Financial Statements TTM (Trailing 12 Months)

Income Statement

Total Revenue (TTM):11.61B
Gross Profit:3.88B
EBITDA:1.83B
Net Income (TTM):−619.00M
Rev Growth (YoY):+5.00%
Earnings Growth (YoY):-
Quarterly earnings growth (YoY):-

Margins

Gross Margin:-
EBITDA Margin:-
Operating Margin:-
Net Margin:-

Per Share

EPS Trailing (TTM):$-1.42

Diluted EPS for the last 12 months: the four quarters ended Sep 30, 2026, from the accounts filed with the SEC on Oct 29, 2026. With negative EPS a P/E means nothing, so it is not shown.

EPS Forward (Est.):$2.04
Revenue Per Share:$22.54
Cash Per Share:-
Book Value:$12.57
Last Dividend:-
Ex-Dividend Date:-
Last Split:-

Balance Sheet & Liquidity

Total cash:1.98B
Total Debt:8.81B
Net Debt (Debt - Cash):6.83B
Debt / Equity:136.02%
Current Ratio:1.79
Quick Ratio:1.00

Cash Flows

Operating Cash Flow:1.64B
Free Cash Flow (FCF):1.22B
FCF Yield (FCF / Market Cap):-
Enterprise Value:19.34B
EV / Revenue:1.67
EV / EBITDA:10.55

Profitability

ROE (Return on Equity):-9.04%
ROA (Return on Assets):2.71%
P/E (trailing):n/a (loss)
P/E (forward):12.48
Price / Book:2.03
PEG Ratio:36.68
52-Week Change:+35.01%
S&P 500 change, 52 weeks:+11.37%

Historical Evolution (Last 4 Years)

Income Statement

Balance Sheet

Cash Flow

EPS and Earnings Per Share

Key EPS Metrics

EPS Trailing (TTM):$-1.42

Diluted EPS for the last 12 months: the four quarters ended Sep 30, 2026, from the accounts filed with the SEC on Oct 29, 2026. With negative EPS a P/E means nothing, so it is not shown.

EPS Forward (Est.):$2.04
P/E (forward):12.48
PEG Ratio:36.68

Growth and Margins

Earnings Growth YoY:-
Quarterly Earnings Growth YoY:-
Rev Growth YoY:-
Net Margin:-
Gross Margin:-
EBITDA Margin:-

Per Share

Revenue Per Share:$22.54
Cash Per Share:-
Book Value:$12.57

Cash Flows (TTM)

Free Cash Flow:1.22B
Operating Cash Flow:1.64B
EBITDA:1.83B
Total Revenue (TTM):11.61B
Net Income (TTM):−619.00M
Fiscal Year (Last):-

EPS Surprise History - Last 4 Quarters

Actual vs. Analyst Estimates · Green = beat expectations · Red = missed

Quarter Period Actual EPS Estimated EPS Difference Surprise % Currency

Ownership Structure

Ownership Distribution

% Insiders:-
% Institutional:-
% Inst. (of Float):-
No. of Institutions:-
Visual distribution
InsidersInstitutionalFree Float

Shares & Short Interest

Shares Outstanding:517,348,188
Float (free shares):514,761,447
Short interest (shares):23,765,665
Short % of float:-
Short Ratio (days to cover):3.45
Short interest, prior month:-
Short Interest Date:-

Governance Score (1=Best, 10=Worst)

Overall risk:-
Audit Risk:-
Board risk:-
Compensation Risk:-
Shareholder rights risk:-

Top Institutional Holders

Position Change: ▲ Increased · ▼ Reduced · = Unchanged

Organization Report Date % Shares No. Shares Value (USD) Change %

Top Mutual Funds

Position Change: ▲ Increased ▼ Decreased = Unchanged

Fund Report Date % Shares No. Shares Value (USD) Change %

Recent Insider Trades

Executive / Insider Title Date Action Shares

Options Chain

CALLS

StrikeLastBidAskVol.O.I.IV

PUTS

StrikeLastBidAskVol.O.I.IV

Baxter International Inc. (BAX) SEC filings: 10-K, 10-Q and 8-K

Direct links to financial reports filed with the SEC.

Type Date Official link
10-Q2026-10-29View filing ↗
8-K2026-08-19View filing ↗
8-K2026-08-18View filing ↗
8-K2026-08-04View filing ↗
8-K2026-07-30View filing ↗
8-K2026-07-14View filing ↗
SD2026-05-29View filing ↗
8-K2026-05-08View filing ↗
10-Q2026-04-30View filing ↗
DEFA14A2026-04-29View filing ↗

Company and Executive Profile

Baxter International Inc., through its subsidiaries, provides a portfolio of healthcare products in the United States. The company operates through three segments: Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals. It offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; inhaled anesthetics; generic injectable pharmaceuticals; surgical hemostat and sealant products; advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space comprising operating room integration technologies, precision positioning devices, and other accessories. The company also provides specialty injectable pharmaceuticals, inhaled anesthetics, and drug compounding services. Its products are used in hospitals, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors' offices, kidney dialysis centers, and patients at home under physician supervision. The company sells its products through direct sales force, independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers. It operates in Eastern Europe, the Middle East, Africa, Latin America, Asia, Western Europe, Canada, Japan, Australia, and New Zealand. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.

General Information

Headquarters:United States
City:Deerfield
Employees:37,500
Sector:Healthcare
Industry:Medical Instruments & Supplies
Website:-

Key Executives

NameTitleAgeTotal pay
Mr. Andrew P. HiderCEO, Pres., Interim Group Pres. of Medical Products & Therapies and Director483.49M
Mr. David S. RosenbloomExecutive VP & General Counsel651.18M
Ms. Maria SorianoGroup President of Infusion Therapies & Platforms-1.10M
Mr. John Terence RogersExecutive VP & CFO56-
Mr. Bernie HeineInterim Chief Accounting Officer & Controller39-
Mr. Charles PatelSenior VP & Chief Information Officer55-
Mr. Kevin MoranVice President & Head of Investor Relations--
Ms. Stacey EisenSVP, Chief Communications Officer & Corporate Marketing and President of Baxter Foundation--

You have seen the engine room

A free account saves your simulator portfolios, your personal portfolio and your Academy progress, synced across devices. And, if you switch it on, the email alert the same day an insider buys stock in their own company.

No card. No spam.

Baxter International Inc. (BAX): Quantitative Analysis

Baxter International Inc. (BAX) — Healthcare — Medical Instruments & Supplies. BAX is in the S&P 500 today. Model factor scores and market data, recalculated every trading day.

So far in 2026, BAX has returned +33.5% against +11.4% for the S&P 500 (SPY): total return, dividends included on both sides, from Dec 31, 2025 to Nov 3, 2026.

BAX ranks 236 of 461 on today's multifactor score, and 32 of the 55 Healthcare companies that score. Its strongest factor is growth (Z 0.80, ranked 48 of 489); its weakest is quality (Z -1.15, ranked 459 of 468). Each factor ranks only the companies with data for it, and the multifactor score only those with all four: that is why the totals differ.

Factor scores

The Z-Score is how many standard deviations the company sits from the index average: 0 is average, positive is better than average, negative is worse.

FactorZ-ScoreRank
Multifactor-0.074236 of 461
Momentum0.436140 of 494 ↑27
Value-0.380322 of 489
Quality-1.151459 of 468
Growth0.79748 of 489

Market data

MetricValue
Price$25.49
Market Cap13.19B
Forward P/E (estimate)12.48
Revenue (last 12 months)11.61B
Price / book2.03
Book value per share$12.57
52-week range$15.73 – $30.00
Dividend yield0.17%
Beta0.67
Average volume6,590,842
Shares outstanding517.35M
Short interest (% of float)7.24% (as of Oct 15, 2026)

When does BAX report earnings? 8 of its last 8, before the open →

What are BAX insiders doing? 43 transactions filed with the SEC, the last one on Sep 2, 2026 →

BAX latest SEC filings

Filing dates on EDGAR, the SEC's public registry. All BAX filings on EDGAR.

Guides: How to read a Quant500 company page · What the S&P 500 is · P/E ratio explained · 10-K, 10-Q and 8-K · all guides

Frequently asked questions about Baxter International (BAX)

When does Baxter International report earnings?

Baxter International has no announced date in the Nasdaq public calendar checked (Nov 3, 2026 to Dec 7, 2026). Of its last 12 earnings announcements: 8 before the open (and 4 with no time on the filing) (SEC filings through Oct 28, 2026). BAX earnings dates and times, quarter by quarter →

Where does Baxter International rank on Quant500?

In the Nov 3, 2026 multi-factor ranking, Baxter International ranks 236 of 461, and 32 of the 55 Healthcare companies that score. The ranking orders S&P 500 companies by the average of four factors (momentum, value, quality and growth) and is recalculated every trading day. It is a model output, not investment advice. The full ranking → How it is calculated →

Have Baxter International insiders bought or sold shares?

SEC Form 4 shows no open-market purchase of Baxter International shares from August 2025 through Nov 3, 2026. Nor any open-market sale. All BAX insider trades →

Does Baxter International pay a dividend?

Yes. Its dividend yield is 0.17% at the Nov 3, 2026 close (annual dividend of $0.04 per share). The latest recorded ex-dividend date is Aug 28, 2026.

What sector is Baxter International in, and which index?

Baxter International is classified in the Healthcare sector (industry: Medical Instruments & Supplies), per the data provider's classification (similar to GICS, not identical). It is in the S&P 500 today. It is one of the 59 S&P 500 companies in that sector. Healthcare stocks →

What is behind these numbers

The concepts on this page, explained from scratch in the Academy. Free, no account.

The whole Academy, course by course →

Data as of Nov 3, 2026. Source: point-in-time SEC fundamentals and closing prices. Method and formulas are on the home page.

The model portfolio, weekly in your inbox

Every Saturday, its week in one minute: how it went, the best and the worst, and which insiders bought with their own money. Plus, the day the model is rebuilt, which stocks come in and which go out. A simulation, not advice. At most one email a week, no ads, no account; one-click unsubscribe. Made by one person: Pol Gracia.

A model portfolio with simulated results, not a personalized recommendation. Your email is used for this only: privacy.

S&P 500 market gravity